Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i and GLP-1RA in Obesity-Related Kidney Disease
NCT06344247Recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin and semaglutide in obesity and chronic kidney disease (CKD) (4 arms), sponsored by Renji Hospital. Primary endpoint: Change of 24-hour urine protein quantification at 48 weeks. Started Sep 2023; status: recruiting.
02
Drugs
dapagliflozinsemaglutide
03
Conditions
obesitychronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06344247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344247.